Moderna Signs Deal for Up to 24 Million RSV Vaccine Doses in Europe
MRNA•Moderna secured a contract with European health authorities for up to 24 million doses of its respiratory syncytial virus vaccine. The deal solidifies Moderna’s expansion in respiratory vaccines and could contribute significant revenue growth over the agreement’s duration.
1. Contract Details
Moderna has entered into an agreement with European health authorities to supply up to 24 million doses of its RSV vaccine. While financial terms and delivery schedule were not disclosed, the volume underscores a sizable commitment from EU member states.
2. Revenue Implications
Deals of this scale in the vaccine market typically translate to low hundreds of millions of dollars in revenue. This contract is poised to bolster Moderna’s sales in its respiratory vaccine segment beyond its COVID-19 franchise.
3. Strategic Expansion
Moderna’s mRNA platform expansion into RSV underscores a strategic push to diversify its product portfolio into established respiratory pathogens. Success in Europe could pave the way for similar agreements in other regions.
4. Market Context
Respiratory syncytial virus poses significant health risks to infants and the elderly, driving European governments to secure preventative vaccines. This purchase reflects heightened focus on RSV mitigation ahead of seasonal peaks.
